En Es
Categories

Industry News


Seegene Partners with Hamilton to Develop Random Access System

By Labmedica International staff writers
28 Sep 2017

Image: Seegene has signed a Memorandum of Understanding (MoU) with Hamilton Company to develop the Seegene Random Access System (Photo courtesy of iStock).Seegene (Seoul, South Korea), a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company (Reno, NV, USA), which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.

The Seegene Random Access System is a molecular diagnostics solution that provides order-to-report on the same day by integrating simultaneous and high multiplex real-time PCR testing on Hamilton’s automated liquid handling platforms, regardless of specimen and assay type. Seegene expects the collaboration to accelerate the development of the Random Access System and to complete the Digitalized Development System, which enables the automation of whole development process from reagent development, clinical studies, manufacturing to quality control.

“To achieve the Seegene Random Access System, the integration of technologies applied in reagent, instrument and software is necessary. Through our collaboration, we will be able to accelerate the accomplishment of ‘Seegene Random Access System’,” said Dr. Jong Yoon Chun, CEO and founder of Seegene. “Molecular diagnostics testing is currently limited to large hospitals or clinical laboratories; however, with the completion of the system, molecular diagnostics utilization will greatly increase as order-to-report on the same day allows hospitals to conduct molecular diagnosis and this will lead to a breakthrough in achieving on-time customized patient care.”



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
More info

More articles about Seegene

14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
09 Jan 2018
Seegene Develops World’s First Multiplex MDx Assays with AI System
Seegene Inc., a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
11 Jan 2022
J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions
The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA; www.microsoft.com) to further enable and expand JJMDC’s secure and compliant digital surgery ecosystem.
Read More
10 Jan 2022
ICU Medical Completes Acquisition of Smiths Medical to Create Leading Infusion Therapy Company
ICU Medical Inc. (San Clemente, CA, USA) has completed its acquisition of Smiths Medical (Minneapolis, MN, USA) from Smiths Group plc that includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical's existing businesses, the combined companies create a leading infusion therapy company.
Read More
05 Jan 2022
Global Portable Ultrasound Scanner Market to Be Driven by Rising Trauma and Accident Cases
The global portable ultrasound scanner market is being driven by an increase in targeted illnesses, rise in trauma & accident cases, surge in demand for less invasive operations, and the emergence of a senior population at a high risk of diseases.
Read More
04 Jan 2022
Global Mammography Workstations Market to Surpass USD 0.19 Billion in 2028 Due to Increasing Prevalence of Breast Cancer
The global mammography workstations market is projected to grow at a CAGR of 6.8% from about USD 0.12 billion in 2020 to more than USD 0.19 billion in 2028, led by increasing prevalence of breast cancer across the world, growing need for early breast cancer diagnosis and treatment, rise in government initiatives to spread breast cancer awareness, and rapid adoption of advanced mammography workstations in hospitals, clinics, and breast care centers.
Read More
30 Dec 2021
Global Ultrasound Device Market to Reach USD 9.5 Billion by 2027 Due to Rising Prevalence of Chronic Disorders
The global ultrasound devices market is projected to grow at a CAGR of 4.73% from USD 7.2 billion in 2021 to USD 9.5 billion by 2027, driven by a rise in the prevalence of chronic disorders such as cancer tumors, gallstones, fatty liver disease, and high spending on the healthcare industry.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions